Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Assessment of revised recruitment standards for asthma in the Australian Defence Force.

Ireland R, Waller M, MacKenzie A, Peake J, Nasveld P.

Mil Med. 2014 Nov;179(11):1384-90. doi: 10.7205/MILMED-D-14-00009.

PMID:
25373070
2.

Self-management and rehabilitation in osteoarthritis: is there a place for internet-based interventions?

Pietrzak E, Cotea C, Pullman S, Nasveld P.

Telemed J E Health. 2013 Oct;19(10):800-5. doi: 10.1089/tmj.2012.0288. Epub 2013 Sep 4. Review.

PMID:
24003979
3.

The health and cost implications of high body mass index in Australian defence force personnel.

Peake J, Gargett S, Waller M, McLaughlin R, Cosgrove T, Wittert G, Nasveld P, Warfe P.

BMC Public Health. 2012 Jun 19;12:451. doi: 10.1186/1471-2458-12-451.

4.

Comparison of self-reported and audiometrically-measured hearing loss in the Australian Defence Force.

Kirk KM, McGuire A, Nasveld PE, Treloar SA.

Int J Audiol. 2012 Apr;51(4):294-8. doi: 10.3109/14992027.2011.625981. Epub 2011 Dec 12.

PMID:
22149463
5.

Self-reported tinnitus and ototoxic exposures among deployed Australian Defence Force personnel.

Kirk KM, McGuire A, Nielsen L, Cosgrove T, McClintock C, Nasveld PE, Treloar SA.

Mil Med. 2011 Apr;176(4):461-7.

PMID:
21539171
6.

Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, McCarthy K, Kanesa-thasan N, Meric C, Reid M.

Hum Vaccin. 2010 Dec;6(12):1038-46. Epub 2010 Dec 1.

7.

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M.

Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.

8.

Dermoscopy in primary care for detection of melanoma.

Kitchener S, McMaster S, Nasveld P.

Int J Dermatol. 2009 Dec;48(12):1397-8. doi: 10.1111/j.1365-4632.2007.03488.x. No abstract available.

PMID:
20415681
9.

Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.

Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W; Tafenoquine Study Team.

Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7.

10.

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.

Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD.

Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1095-101. doi: 10.1016/j.trstmh.2008.04.024. Epub 2008 Jun 9.

PMID:
18541280
11.

Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.

Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD.

Antimicrob Agents Chemother. 2007 Aug;51(8):2709-15. Epub 2007 May 21.

12.

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.

Kitchener S, Nasveld P, Edstein MD.

Am J Trop Med Hyg. 2007 Mar;76(3):494-6.

14.

Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Charles BG, Blomgren A, Nasveld PE, Kitchener SJ, Jensen A, Gregory RM, Robertson B, Harris IE, Reid MP, Edstein MD.

Eur J Clin Pharmacol. 2007 Mar;63(3):271-8. Epub 2007 Jan 11.

PMID:
17216435
15.

Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis.

Edstein MD, Nasveld PE, Kocisko DA, Kitchener SJ, Gatton ML, Rieckmann KH.

Trans R Soc Trop Med Hyg. 2007 Mar;101(3):226-30. Epub 2006 Jun 30.

PMID:
16814823
16.

Who attends skin cancer screening in the suburbs?

Kitchener SJ, McMaster S, Nasveld P.

Aust N Z J Public Health. 2006 Jun;30(3):290-1. No abstract available.

PMID:
16800212
17.

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF.

Vaccine. 2006 Feb 27;24(9):1238-41. Epub 2005 Sep 23.

PMID:
16213632
18.

Adequate primaquine for vivax malaria.

Kitchener S, Nasveld P, Bennett S, Torresi J.

J Travel Med. 2005 May-Jun;12(3):133-5.

PMID:
15996441
19.

Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor.

Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD.

Med J Aust. 2005 Feb 21;182(4):168-71.

PMID:
15720172
20.

Intradermal boosting of Japanese encephalitis vaccination.

Kitchener S, Baade L, Brennan L, Nasveld P.

J Travel Med. 2004 May-Jun;11(3):182-3. No abstract available.

PMID:
15710061
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk